A logo on the Sanofi exhibition space at the Viva Technology conference dedicated to innovation and startups at Porte de Versailles exhibition center in Paris, France, on June 15, 2022.
Benoit Tessier | Reuters
Two weeks ago, Monique Griffin got a troubling email.
The French drugmaker Sanofi told her that a shipping delay had interrupted supply of the drug that she relies on to manage her rare muscle-wasting disease. Her next infusion was canceled. Griffin, who is 51 and uses a wheelchair due to Pompe disease, fears what will happen if the shortage isn't resolved soon.
"You're basically letting the disease take over again," she said. "It's terrifying."
More than three months after initial reports of supply problems with treatments for Pompe disease, the disruption drags on, with more patients learning their infusions have been canceled. Sanofi said it has made progress restoring the supply to patients in some countries, but added that shipping delays could interrupt infusions for some U.S. patients through the end of November.
For more stories like this, sign up for the CNBC Cures newsletter.
Sanofi spokesman Evan Berland said there were no issues with drug quality and the company is "committed to ensuring that the most vulnerable patients receive treatment first during this period." Berland recommended patients speak with a health professional before taking another treatment. "These medicines are not interchangeable," he said.
In a statement, the Food and Drug Administration said "patient access to these treatments is a priority for the agency and we have offered our assistance to Sanofi on anything needed to help ensure all patient needs are met."
About one in every 19,000 babies is born with Pompe disease, which is named after the Dutch pathologist who discovered the condition nearly a century ago.
Patients lack an enzyme for breaking down a complex sugar, causing a toxic buildup of glycogen inside their cells. Their muscles weaken and their heart can become enlarged. They have trouble breathing and eating. Left untreated, the disease is often fatal.
Sanofi's Lumizyme and a second-generation version, Nexviazyme, replace the missing enzyme, protecting the patient's muscles. Patients typically receive Sanofi's drugs every two weeks.
"It's a lifeline," said Jenna Yarborough, a rare disease advocate whose two children with Pompe disease have not been affected by the drug shortage.
While Pompe disease patients rely on Sanofi's drugs, several other treatments have entered clinical trials, including separate gene therapies from AskBio and Astellas Pharma.
Monique Griffin uses a wheelchair due to Pompe disease and had a transfusion canceled due to drug shortages.
Monique Griffin
Sanofi says the drug shortage is the result of issues at its manufacturing facility in Ireland, which public documents show the company has known about for several months. The FDA inspected the plant between January 12 and January 20, 2026 and found violations involving two unrelated drugs. The company began responding to the violations in February, but on June 22, the FDA sent the company a warning letter saying it had still not addressed the "underlying failure" to comply with manufacturing requirements. Addressing the FDA's ongoing concerns has contributed to the supply disruption of the Pompe therapies, according to Sanofi.
There's a sense of frustration within the Pompe community that the company did not do enough to warn patients about the potential for a supply disruption. Ryan Colburn, a person living with Pompe who is active in the advocacy space, says many patients were unaware of the manufacturing issues at Sanofi and were left with no way to prepare for them. "The lack of proactive transparency and apparent lack of buffer are of huge concern for any medicine that people's lives and well-being depend on access to," Colburn said.
A spokesperson for Sanofi responded, "As the situation evolved, and the extent of the disruption became clearer, we engaged global and U.S. patient advocacy organizations, patients and clinicians to inform them, and we have worked to continue to keep these groups and individuals updated through regular communications. We remain committed to continuity of care and to transparent, ongoing communication with the Pompe community as we work to stabilize supply."
Chelsey McGee's 10-year-old son Logan has taken Lumizyme every two weeks since he was diagnosed with Pompe disease as an infant. While his infusions haven't been canceled yet, she's concerned that missing even one appointment will damage his heart. Sanofi's drug has kept him healthy enough to play soccer.
"It's important that we stay on his timeline and keep his heart healthy," she said.
McGee, who lives in Minneapolis, is frustrated by what she says is a lack of transparency from Sanofi. She discovered the FDA cited the pharmaceutical company for manufacturing problems by searching the agency's website, not from the company.
Griffin, who lives in Orlando, has taken Lumizyme since 2010 when she was diagnosed with an adult-onset version of the disease. The diagnosis came after she became so fatigued that she fell while carrying groceries and suffered a concussion.
She knows what it's like to go without her infusions. She missed a few appointments earlier this year due to an insurance mix-up. She likened it to having "a really bad flu." She became extremely fatigued, struggled to breathe and started to feel pain in her legs, arms and back.
Pompe is a progressive disease, meaning it gets worse over time. She worries most about losing the strength to breathe. She sleeps with assisted ventilation.
She works in the theme parks industry and is hoping to attend a conference this week. While her Lumizyme infusions remain on hold, she hopes to get through the week of meetings "on caffeine and goodwill."
CNBC Cures is underwritten by Alexion, AstraZeneca Rare Disease and BridgeBio.
Source: CNBC · Gerry Smith, Brad Quick
At a glance
- Topic
- Business
- Country
- 🇺🇸 US
- Publisher language
- EN
- Added to Allnira